Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to examine the safety and tolerability of treatment with concurrent Sacituzumab Govitecan (SG) and adaptive radiation therapy. The main objective is to establish the safety, tolerability, and feasibility of bladder preservation therapy treatment with concurrent SG and adaptive image-guided radiation therapy for participants with localized MIBC. Participants will receive the study drug, SG, through an IV once weekly on days 1 and 8 of each 21-day treatment cycle. The first cycle of SG will begin 21 days prior to the scheduled start of radiation therapy. The second and third cycles of SG will be given while the participant is receiving radiation therapy. Participants will be asked to undergo computed tomography (CT) and magnetic resonance imaging (MRI) pre-and post-treatment. Participation in the research will last up to 5 years, depending on treatment outcomes, with a treatment period of 8 weeks and a study follow-up period of up to 2-5 years thereafter, and a survival follow-up, with only phone call communication from years 3-5.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony razem pęcherza moczowego (invasive bladder cancer - T2-T4aN0M0)
- •Brak wcześniejszej chemioterapii dla tego nowotworu
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu (ECOG ≤ 2)
- •Prawidłowe funkcje wątroby (enzym AST/ALT, bilirubina w normie)
- •Wystarczająca liczba komórek krwi (neutrofile, płytki, hemoglobina w normie)
- •Prawidłowa funkcja nerek (czyszczenie kreatyniny ≥ 30 mL/min)
- •Wystarczająca funkcja pęcherza moczowego do rozważenia jego zachowania
- •Wykonane usunięcie guza z pęcherza (TURBT) w ciągu 60 dni przed leczeniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, United States
Trial contact
Shilpa Gupta, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.